Sign Out
Anticholinergic agents: Although Ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
Beta-adrenergic agents: Co-administration with other sympathomimetic agents may increase risk of adverse cardiovascular events.
Beta-receptor blocking agents: Salbutamol and a beta-receptor blocking agent inhibit each other's effect.
Diuretics: The ECG changes and/or hypokalemia which may result from the administration of non-potassium sparing diuretics (e.g., loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Monoamine oxidase inhibitors (MAOIs) or Tricyclic antidepressant (TCAs): Concomitant administration with these agents may potentiate Salbutamol's effect on the cardiovascular system.
